{"prompt": "['PREDM', 'Page 9', 'reduction impact on long-term cardiac morbidity and mortality in this high-risk', 'population.', 'Diabetes prevention and control reduces cardiovascular risk in the general', 'population: In the general adult population, diabetes is a well-established', 'cardiovascular risk factor. Among adults with diabetes, cardiovascular disease is', 'the leading cause of death and occurs up to 15 years earlier than in non-diabetics.6', 'Improvement in glucose control decreases this risk and for every 1% reduction in', 'hemoglobin Alc (HbA1c) towards a value of <6% there is an estimated 11-16%', 'decrease in cardiovascular events including stroke, myocardial infarction and', 'heart failure.7 Additionally, adults with diabetes have a 60% increase in risk for', 'all-cause mortality with an 80% increase in risk of death from vascular causes', 'compared to those who do not have diabetes. 8 The specific impact of improved', 'glucose control and diabetes prevention on mortality and cardiac morbidity in', 'adult survivors is unknown and preliminary data generated from this pilot study', 'would be used to design a randomized, large-scale trial of efficacy for diabetes', 'prevention in survivors.', 'Diabetes prevention is effective in the general population. Prediabetes is defined', 'as a fasting plasma glucose (FPG) of 100-125 mg/dl or hemoglobin Alc (HbAlc)', '5.7-6.4% in the absence of overt diabetes. In the general population it is estimated', 'that without intervention, 4-10% of prediabetics will become diabetic over one', 'year. 9,10 Both pharmacologic therapy with metformin, a biguanide class oral', 'hypoglycemic agent that reduces hepatic glucose production and impacts', 'anaerobic glucose metabolism and uptake at the level of the intestine, 11 and', 'intensive lifestyle intervention used in the Diabetes Prevention Program (DPP)', 'have each been established to prevent progression to diabetes among prediabetic', 'adults in the general population. 9,12 In this landmark trial, intensive lifestyle', 'intervention included a 16-week core-curriculum led by a lifestyle coach and', 'focused on diet, exercise and behavioral strategies targeting 7% weight loss and at', 'least 150 minutes per week of moderate intensity physical activity (brisk walking', 'or biking), and pharmacologic therapy was 850 mg metformin immediate release', 'twice daily. 13 At study completion, with an average follow-up time of 2.8 years,', 'lifestyle intervention reduced the incidence of diabetes by 58% and metformin by', '31%, compared to placebo. 12 However, in the youngest subset of participants (25-', '44 years, the target age range for this application), metformin and lifestyle change', 'had similar efficacy with the incidence of diabetes reduced by 44% in the', 'metformin and 48% in the lifestyle group. 12 Despite this, metformin is not', 'commonly used in prediabetic adults. Less than 1% reported metformin use in the', 'National Health and Nutrition Examination Survey (NHANES).', '14', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date NUMBER: 00-00-00 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 10', 'Whether treatment-related diabetes is preventable is unknown: Preliminary data', 'from the St. Jude Lifetime Cohort (SJLIFE) suggests prediabetes prevalence in', 'survivors is near twice that of similarly aged controls (Table 1). Still, it is', 'unknown if interventions utilized in the general population are feasible or', 'efficacious in this high-risk population.', 'Table 1. Prediabetes and', 'Prediabetes', 'Diabetes', 'Diabetes in SJLIFE', 'Participants at Baseline', 'N', 'N', '%', 'N', '%', 'by Age', 'Survivors', '18-24 yrs', '1012', '172', '17.0', '26', '2.6', '25-34 yrs', '1465', '412', '28.1', '71', '4.8', '35-44 yrs', '792', '328', '41.4', '89', '11.2', '45-54 yrs', '230', '107', '46.5', '38', '16.5', '55-64 yrs', '30', '13', '43.3', '5', '16.7', 'Controls', '18-24 yrs', '85', '8', '9.4', '1', '1.2', '25-34 yrs', '157', '23', '14.6', '4', '2.5', '35-44 yrs', '136', '31', '22.8', '9', '6.6', '45-54 yrs', '53', '14', '26.4', '7', '13.2', '55-64 yrs', '17', '5', '29.4', '0', '0.0', 'Table 2. Potentially Eligible Participants', '2.2 Rationale', 'from SJLIFE Age 18-<45 Known to be', 'Type 2 diabetes has become an', 'Prediabetic (N=603)', 'Age at diagnosis, years', '6.55', '2.9-12.7', 'epidemic in the US, affecting 12%', '(median, IQR)', 'of the adult population. 15 Among', 'N', '%', 'survivors, our data in the SJLIFE', 'Age as of 12/1/2019', '18-24 years', '27', '4.5', 'cohort, consistent with prior', '25-34 years', '237', '39.3', 'studies, demonstrates an increased', '35-<45 years', '339', '56.2', 'prevalence of diabetes among', 'Exposure Type', 'adult survivors; specifically,', 'Pancreatic Radiation', '234', '38.8', 'Cranial Radiation', '197', '32.7', 'among those in middle adulthood', 'Total Body Irradiation', '26', '4.3', '(35-64 years), 12.5% were', 'Corticosteroids', '275', '45.6', 'diabetic (Table 1). In the original', 'Asparaginase', '189', '31.3', 'Bone Marrow Transplant', '54', '9.0', 'Diabetes Prevention Program', 'Gender', '(DPP) trial performed in the', 'Male', '385', '63.8', 'overweight, general adult', 'Female', '218', '36.2', 'population with prediabetes, 72%', 'Race', 'White, Non-Hispanic', '476', '78.9', 'of participants randomized to the', 'Other', '127', '21.1', 'metformin arm took 80% of', 'BMI Category (kg/m\u00b2)', 'prescribed metformin dose. 12', 'Underweight, <18.5', '20', '3.3', 'Additionally, in the DPP, 74% of', 'Healthy weight, 18.5-24.9', '142', '23.6', 'Overweight, 25.0-29.9', '177', '29.3', 'lifestyle participants met the 150', 'Obese, >30.0', '264', '43.8', 'min/week activity goal based on', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}